1. P876: INCIDENTAL DISCOVERY OF PROBABLE PATHOGENIC GERMLINE VARIANTS IN MULTIPLE MYELOMA PATIENTS UNDERGOING SOMATIC GENOMIC PROFILING. (23rd June 2022) Authors: Thibaud, S.; Brander, T.; Balwani, M.; Mouhieddine, T.; Melnekoff, D.; Van Oekelen, O.; Lagana, A.; Houldsworth, J.; Chari, A.; Richter, J.; Sanchez, L.; Richard, S.; Rodriguez, C.; Rossi, A.; Cho, H. J.; Jagannath, S.; Onel, K.; Parekh, S. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 769 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P961: CILTACABTAGENE AUTOLEUCEL, A BCMA-DIRECTED CAR-T CELL THERAPY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: 2-YEAR POST LPI RESULTS FROM THE PHASE 1B/2 CARTITUDE-1 STUDY. (23rd June 2022) Authors: Lin, Y.; Martin, T.; Berdeja, J. G.; Jakubowiak, A.; Agha, M.; Cohen, A. D.; Deol, A.; Htut, M.; Lesokhin, A.; Munshi, N. C.; O'Donnell, E.; Jackson, C. C.; Yeh, T.-M.; Banerjee, A.; Zudaire, E.; Madduri, D.; Zhou, C.; Pacaud, L.; Usmani, S. Z.; Jagannath, S. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 851 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P971: ADJUSTED COMPARISON OF PATIENT REPORTED OUTCOMES FROM CARTITUDE-1 AND LOCOMMOTION COMPARING CILTACABTAGENE AUTOLEUCEL VERSUS REAL WORLD CLINICAL PRACTICE IN TRIPLE-CLASS EXPOSED MULTIPLE MYELOMA. (23rd June 2022) Authors: Weisel, K.; Mateos, M.-V.; Vincent, L.; Martin, T.; Berdeja, J. G.; Jakubowiak, A.; Jagannath, S.; Lin, Y.; Thilakarathne, P.; Ghilotti, F.; Diels, J.; Haefliger, B.; Hague, C.; Gonzalez, A.; Schecter, J. M.; Gries, K. S.; Strulev, V.; Nesheiwat, T.; Pacaud, L.; Einsele, H. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 861 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. S189: EARLY, DEEP, AND DURABLE RESPONSES, AND LOW RATES OF CRS WITH REGN5458, A BCMAXCD3 BISPECIFIC ANTIBODY, IN A PHASE 1/2 FIRST-IN-HUMAN STUDY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA. (23rd June 2022) Authors: Zonder, J. A.; Richter, J.; Bumma, N.; Brayer, J.; Hoffman, J. E.; Bensinger, W. I.; Wu, K. L.; Xu, L.; Chokshi, D.; Boyapati, A.; Cronier, D.; Houvras, Y.; Rodriguez Lorenc, K.; Kroog, G. S.; Dhodapkar, M. V.; Lentzsch, S.; Cooper, D.; Jagannath, S. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 90 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗